Quebec Heart & Lung Institute, Laval University 2725 Chemin Ste-Foy, G1V 4GS Quebec City, Quebec, Canada.
J Invasive Cardiol. 2020 Aug;32(8):283-288. doi: 10.25270/jic/20.00037.
The crossover balloon occlusion technique (CBOT) facilitates primary access hemostasis in patients undergoing transfemoral transcatheter aortic valve replacement (TAVR). The CBOT is usually performed through the contralateral femoral artery. The aim of this study was to evaluate, in patients undergoing TAVR, the safety and feasibility of transradial CBOT using the new Oceanus balloon dilatation catheter (iVascular).
This multicenter study included 104 patients (mean age, 81 ± 7 years; 43% women) undergoing transfemoral TAVR. A modified CBOT through the radial artery was performed in all patients with the Oceanus balloon catheter. Data regarding transradial CBOT, balloon performance, vascular complications, and 30-day clinical events were recorded.
Up to 21% of patients had a height >170 cm and 17% presented with severe aortic/iliofemoral tortuosity. The transradial CBOT (left radial 74%, right radial 26%) was performed using either the 140 cm Oceanus (37.5%) or the 200 cm Oceanus (62.5%) balloon catheter. The balloon reached the femoral artery in all patients, and balloon inflation achieved an appropriate vessel closure in 98%. There were no complications related to the balloon catheter, and only 1 patient (1.0%) suffered a minor vascular complication related to the secondary radial access. The 30-day rates of primary access major vascular complications and death were 3.8% and 1.9%, respectively.
In patients undergoing transfemoral TAVR, transradial CBOT with the Oceanus balloon dilatation catheter was feasible and safe. A balloon length up to 200 cm allowed the use of this technique (from right or left radial access) in all patients regardless of patient height or the presence of a challenging vascular anatomy.
交叉球囊阻断技术(CBOT)有助于经股动脉行经导管主动脉瓣置换术(TAVR)患者的初次入路止血。CBOT 通常通过对侧股动脉进行。本研究旨在评估在接受 TAVR 的患者中,使用新型 Oceanus 球囊扩张导管(iVascular)经桡动脉进行 CBOT 的安全性和可行性。
这项多中心研究纳入了 104 名(平均年龄 81±7 岁,43%为女性)接受经股动脉 TAVR 的患者。所有患者均使用 Oceanus 球囊导管进行改良的桡动脉 CBOT。记录经桡动脉 CBOT、球囊性能、血管并发症和 30 天临床事件的数据。
多达 21%的患者身高>170cm,17%存在严重的主动脉/髂股动脉迂曲。经桡动脉 CBOT(左桡动脉 74%,右桡动脉 26%)使用 140cm Oceanus(37.5%)或 200cm Oceanus(62.5%)球囊导管进行。所有患者的球囊均到达股动脉,球囊充气使血管闭塞达到合适程度的比例为 98%。无与球囊导管相关的并发症,仅有 1 例(1.0%)患者因次级桡动脉入路出现轻微血管并发症。30 天内初次入路主要血管并发症和死亡的发生率分别为 3.8%和 1.9%。
在接受经股动脉 TAVR 的患者中,使用 Oceanus 球囊扩张导管经桡动脉进行 CBOT 是可行且安全的。球囊长度可达 200cm,使得该技术(经右或左桡动脉入路)可用于所有患者,无论患者身高或存在挑战性的血管解剖结构如何。